Peabody Internal Medicine, INC.
Peabody Internal Medicine, INC. was paid $392K by Medicaid between Jan 2018 and Nov 2024, across 75 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 37% of everything it billed.
33Billing provider infoPEABODY INTERNAL MEDICINE, INC.
MILLINGTON, TN 38053
MILLINGTON, TN 38053
33aNPI1285723403assigned 10/12/2006
33bProvider typeSpecialist
28Total paid$392K
24GClaims45,838
24DCodes billed75
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Specialist providers in Tennessee
Rank by total paid#62 of 252
Median peer was paid$57K
This provider vs. median6.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,770 | $72K | |
| 2019 | 7,706 | $64K | |
| 2020 | 7,025 | $64K | |
| 2021 | 10,281 | $88K | |
| 2022 | 9,157 | $66K | |
| 2023 | 1,310 | $9K | |
| 2024incomplete | 3,589 | $30K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 37% | 6,925 | 5,559 | $144K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 37% | 9,721 | 7,354 | $144K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 5.7% | 3,727 | 2,076 | $22K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.8% | 662 | 442 | $11K |
| 93000 | 2.4% | 1,895 | 1,415 | $10K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.2% | 162 | 100 | $9K |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | 1.3% | 836 | 635 | $5K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.2% | 720 | 439 | $5K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.2% | 321 | 189 | $5K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.0% | 138 | 77 | $4K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 111 | 95 | $4K |
| 81002 | <1% | 3,653 | 2,923 | $4K |
63 more codes
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 1,051 | $3K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 126 | $3K |
| 82962 | <1% | 2,388 | $3K | |
| 20610 | <1% | 144 | $3K | |
| 90688 | <1% | 356 | $2K | |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | <1% | 904 | $2K |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 1,032 | $2K |
| 87428 | <1% | 77 | $1K | |
| 94760 | <1% | 2,872 | $843.39 | |
| 90658 | <1% | 62 | $769.88 | |
| 93922 | <1% | 57 | $769.64 | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 598 | $720.82 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 101 | $630.84 |
| 99490 | Ccm add 20min | <1% | 240 | $578.01 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 161 | $546.99 |
| 99497 | <1% | 12 | $530.70 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 25 | $520.50 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 65 | $432.83 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 80 | $403.46 |
| 90662 | <1% | 299 | $395.14 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 140 | $263.46 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 220 | $168.77 |
| G0008 | Administration of influenza virus vaccine | <1% | 594 | $125.59 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 956 | $118.87 |
| 99406 | <1% | 57 | $117.26 | |
| 99397 | <1% | 146 | $105.97 | |
| 87210 | <1% | 39 | $90.45 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 119 | $84.96 |
| 87220 | <1% | 36 | $75.46 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 13 | $67.18 |
| 82270 | <1% | 107 | $55.39 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 156 | $47.13 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 37 | $30.39 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 44 | $28.43 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 502 | $0.61 |
| 1159F | 0% | 199 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 66 | $0.00 |
| 1160F | 0% | 201 | $0.00 | |
| 3078F | 0% | 91 | $0.00 | |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 0% | 241 | $0.00 |
| 3288F | 0% | 87 | $0.00 | |
| G9791 | Most recent tobacco status is tobacco free | 0% | 15 | $0.00 |
| G8482 | Influenza immunization administered or previously received | 0% | 23 | $0.00 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 31 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 35 | $0.00 |
| 1125F | 0% | 597 | $0.00 | |
| G9664 | Patients who are currently statin therapy users or received an order (prescription) for statin therapy | 0% | 83 | $0.00 |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 306 | $0.00 |
| 3079F | 0% | 20 | $0.00 | |
| 4010F | 0% | 33 | $0.00 | |
| 3008F | 0% | 453 | $0.00 | |
| 3074F | 0% | 100 | $0.00 | |
| 1036F | 0% | 52 | $0.00 | |
| 1170F | 0% | 134 | $0.00 | |
| 3044F | 0% | 16 | $0.00 | |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 91 | $0.00 |
| 1111F | 0% | 65 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 52 | $0.00 |
| G9906 | Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) | 0% | 17 | $0.00 |
| 1126F | 0% | 17 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 59 | $0.00 |
| 1101F | 0% | 49 | $0.00 | |
| G9902 | Patient screened for tobacco use and identified as a tobacco user | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBAIG, ABDULLAH (PRESIDENT)